An interventional study of Magnetic resonance elastography (MRE) in Cushing Syndrome and Metabolic Syndrome, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-25.
Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Diagnostic
The main hypothesis of the HEPACORT study is that upon diagnosis of endogenous Cushing's syndrome, significant liver fibrosis may be present, particularly in the most severe forms of Cushing's syndrome.
the HEPACORT study is the first exploratory study to assess the severity of liver fibrosis in patients with Cushing's syndrome or suspected of presenting by Magnetic Resonance Elastography (MRE).
123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.
This study's planned enrollment of 21 is below the median of 44 across 58 interventional studies indexed under Cushing Syndrome.
Browse Cushing Syndrome studies →Central Hospital, Nancy, France is the lead sponsor of 798 studies on the registry; 186 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with proven autonomic cortisol secretion (Cushing's Syndrome)
Device: Magnetic resonance elastography (MRE)
Patients with possible autonomic cortisol secretion (Suspected Cushing's Syndrome)
Device: Magnetic resonance elastography (MRE)
Patients with metabolic syndrome
Device: Magnetic resonance elastography (MRE)
Magnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues
Estimation of the severity of hepatic fibrosis by MRE (kPa).
Estimation of the severity of hepatic fibrosis in kPa by a non-invasive elastography method : magnetic resonance elastography.
Time frame: Baseline (day 0)
Evaluation of the presence of hepatic fibrosis by MRE (kPa).
Evaluation of the presence of hepatic fibrosis by ERM : ERM value ≥ 72.5 kPa.
Time frame: Baseline (day 0)
Evaluation of the association between hyperglycemia (blood glucose by g/L) with the presence of Fibrosis by MRE (kPa).
Time frame: Baseline (day 0)
Evaluation of the association between high blood pressure (mmHg) with the presence of Fibrosis by MRE (kPa).
Time frame: Baseline (day 0)
Evaluation of the association between overweight (kg) with the presence of Fibrosis by MRE (kPa).
Time frame: Baseline (day 0)
Evaluation of the association between osteoporosis (g/cm²) with the presence of Fibrosis by MRE (kPa).
Time frame: Baseline (day 0)
Evolution of transaminases (UI/L) between the diagnosis and the last visit.
Time frame: 1 year
Evolution of GGT (gamma-glutamyl transferase) (UI/L) between the diagnosis and the last visit.
Time frame: 1 year
Evolution of ALP (Alkaline Phosphatases) (UI/L) between the diagnosis and the last visit
Time frame: 1 year
Evolution of Bilirubin (mg/L) between the diagnosis and the last visit.
Time frame: 1 year
Evolution of Albumin (g/L) between the diagnosis and the last visit.
Time frame: 1 year
Evolution of platelets (platelets/mm3) between the diagnosis and the last visit.
Time frame: 1 year
Evolution of ferritin (ng/mL) between the diagnosis and the last visit.
Time frame: 1 year
Started Oct 2023 (actual). Primary completion is estimated for Feb 2026, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →